Gilead Finalizes $7.1B Arcellx Acquisition, Securing Full Control of Key CAR T-Cell Therapy

summarizeSummary

Gilead Sciences has completed its acquisition of Arcellx for approximately $7.1 billion, gaining full ownership of the investigational CAR T-cell therapy anito-cel and streamlining its development for multiple myeloma.

check_boxKey Events

• Acquisition of Arcellx Completed

  Gilead Sciences has finalized its acquisition of Arcellx, Inc., making it a wholly-owned subsidiary. This follows the regulatory approvals reported on April 17, 2026, and prior news of the acquisition completion.

• Transaction Valued at $7.1 Billion

  The aggregate funds used to consummate the tender offer and merger totaled approximately $7.1 billion, with an implied equity value of $7.8 billion.

• Contingent Value Right (CVR) Issued

  Arcellx shareholders received $115.00 per share in cash plus one CVR of $5.00 per share, contingent on anito-cel sales exceeding $6.0 billion by December 31, 2029.

• Full Control of Anito-cel Secured

  The acquisition provides Gilead with full ownership and control of anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell therapy for multiple myeloma, eliminating future profit-share and royalty obligations.

auto_awesomeAnalysis

This 8-K filing officially confirms the completion of Gilead's significant acquisition of Arcellx, a strategic move that was previously announced and anticipated. The transaction, valued at approximately $7.1 billion in aggregate funds, grants Gilead full control over anito-cel, a promising BCMA-directed CAR T-cell therapy. While the acquisition is expected to be dilutive to Gilead's EPS in the short term (2026-2027), it is projected to become accretive from 2028 onwards, subject to FDA approval. The deal structure, including a contingent value right (CVR) tied to future sales performance, aligns long-term incentives and underscores Gilead's commitment to expanding its oncology pipeline through its Kite subsidiary. Investors should monitor the integration of Arcellx's assets and the progress of anito-cel through regulatory pathways.